Your cart is currently empty!
Category: Metastatic Melanoma
Atezolizumab
Description
This page contains brief details about the drug atezolizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Atezolizumab is an anticancer drug belonging to the group of medicines called Programmed death ligand – 1 inhibitor (PDL-1). It was officially approved for its medical use in the year 2016.
Mechanism of Action of Atezolizumab
Atezolizumab is a humanized monoclonal antibody that belongs to the category of programmed death ligand – 1. Programmed death ligand is a protein that facilitates the suppression of T-cells by binding with immune and tumor cells. This leads to a poor immune response against cancer cells. Atezolizumab Injection acts against the signals of programmed death ligand – 1 and improves immune response by exhibiting specific cytotoxic activity.
Uses of Atezolizumab
Atezolizumab is indicated for various types of cancer as a monotherapy and also along with other anticancer medications. It is usually prescribed to treat urothelial carcinoma, liver cancer (hepatocellular carcinoma), small cell and non-small cell lung cancer, triple-negative breast cancer, and melanoma.
Atezolizumab Dosage available
Atezolizumab Injection is intended for intravenous administration. Your physician will inject this medicine as an infusion for the first 60 minutes and if it is well tolerated, the subsequent infusions will be administered for 30 minutes.
Atezolizumab Injection is available as a single-use vial in doses 840mg/14ml and 1200mg/20ml. The ideal dosing for urothelial carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, and melanoma is 840mg every two weeks, 1200mg every 3 weeks, or 1680mg every four weeks.
Trametinib
Description
This page contains brief details about the drug trametinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Trametinib was approved by the U.S. Food and Drug Administration (FDA) in May 2013 for treating unresectable or metastatic melanoma.
Mechanism of Action of Trametinib
Trametinib is a medication called a mitogen-activated protein kinase (MAPK) kinase inhibitor. It inhibits the activity of the MEK enzyme, which is part of the MAPK pathway that is overactive in many cancer cells. In normal cells, the MAPK pathway plays an important role in regulating cell growth, differentiation, and survival. This pathway can become overactive and contribute to uncontrolled cell growth and tumour formation. It blocks the activity of the MEK enzyme, which is a key component of the MAPK pathway. Doing so helps slow down or stop the growth and spread of cancer cells with these specific genetic mutations. This can lead to a reduction in the size of tumours and an improvement in symptoms for patients with advanced or metastatic cancers.
Uses of Trametinib
Unresectable or metastatic melanoma
Non-small cell lung cancer in combination with Dabrafenib
Advanced or metastatic thyroid cancer
Metastatic solid tumours
Trametinib Dosage available
Trametinib is typically administered orally as a tablet or capsule taken by mouth. The dose and frequency of it will depend on the specific type of cancer being treated and the patient’s health status. For the treatment of melanoma, trametinib is usually taken once daily, either with or without food. It may be taken simultaneously as dabrafenib, another targeted therapy drug used in combination with trametinib for melanoma. In the management of non-small cell lung cancer, trametinib is usually taken once daily, at the same time as dabrafenib.